SINOVAC BIOTECH LTD (SVA)
As-reported financials and SEC filings for SINOVAC BIOTECH LTD. The latest annual period is FY2025. Financial statements come straight from the company’s EDGAR filings; valuation figures such as P/E and market cap use market data.
About SINOVAC BIOTECH LTD
Sinovac Biotech Ltd is a China-based biopharmaceutical company that researches, develops, manufactures, and commercializes vaccines for preventing human infectious diseases. Its vaccine portfolio includes products for hepatitis A and B, influenza, COVID-19, pneumococcal disease, poliomyelitis, mumps, varicella, rabies, tetanus, and hand, foot and mouth disease. The company serves markets in China and internationally through subsidiaries and joint ventures in multiple countries.
Snapshot
Fundamentals are from SEC filings for FY2025, the latest annual period (ended December 31, 2025). P/E and market cap are derived from stored market prices, last retrieved on a rolling basis and typically within the past week.
What changed at Sinovac Biotech
- Revenue grew 6.8% to $386M in FY2025, after a 23.1% decline the year before.
- Operating margin is now a 127.0% loss in FY2025, from 91.0% in FY2021.
- Free cash flow was negative $561M in FY2025.
- Net income turned to a $199M loss in FY2025, from a $41M profit in FY2024.
Computed from the as-reported figures in the statements below. A change we cannot state from filed figures is left out rather than estimated.
Peer comparison
Where Sinovac Biotech’s fundamentals sit among the 198 pharmaceutical companies. Each figure is ranked only against peers that report it, from lowest (left) to highest (right).
Sinovac Biotech’s FCF margin of -145.4% is the lowest of the 110 pharmaceutical companies reporting it. Sinovac Biotech’s operating margin of -127.0% ranks in the 2nd percentile of the 113 pharmaceutical companies reporting it. Sinovac Biotech’s net margin of -51.5% ranks in the 11th percentile of the 122 pharmaceutical companies reporting it.
No reported insider transactions (codes P/S) in the last 90 days. For context, about 15% of companies in the universe saw any reported insider purchase (code P) in the same window. Browse insider activity →
Percentiles describe where a figure sits among industry peers reporting it (100th = highest). They are position within a peer group, not a rating, and not investment advice.
Short interest
Total shares sold short as of each twice-monthly FINRA settlement. Rising short interest means more investors are positioned against the stock; days to cover estimates how many trading days of average volume that position represents.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 2026-08-14 | 82.2K | 0.0% | 999.99 |
| 2026-07-31 | 82.2K | 0.0% | 999.99 |
| 2026-07-15 | 82.2K | 0.0% | 999.99 |
| 2026-06-30 | 82.2K | 0.0% | 999.99 |
| 2026-06-15 | 82.2K | -0.7% | 999.99 |
| 2026-05-29 | 82.7K | 0.0% | 999.99 |
| 2026-05-15 | 82.7K | -0.0% | 999.99 |
| 2026-04-30 | 82.8K | 0.0% | 999.99 |
Source: FINRA Consolidated Short Interest. FINRA is the owner and source of the FINRA-supplied data, which is included at no additional charge for your own personal or professional use; republishing or redistributing it is not permitted. Settlement dates are shown; FINRA publishes each settlement about nine business days later, so the latest figure can be two to four weeks old. Not presented as a percentage of float. No FINRA endorsement of this product is implied. Not investment advice.
Income statement (as reported)
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Revenue | $386.0M | $361.4M | $470.2M | $1.47B | $19.37B |
| Gross profit | $262.0M | $220.7M | $323.3M | $815.2M | — |
| Operating income | $-490.1M | $-505.5M | $-714.0M | $-509.0M | $17.62B |
| Net income | $-198.8M | $40.7M | $-120.9M | $-60.0M | $14.12B |
| Diluted EPS | $-0.83 | $1.27 | $-0.19 | $0.20 | $113.44 |
Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.
Balance sheet (as reported)
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Cash and equivalents | $488.2M | $335.3M | $1.12B | $3.88B | $11.61B |
| Current assets | $7.06B | $10.64B | $11.60B | $11.30B | $14.94B |
| Total assets | $8.54B | $12.34B | $13.61B | $14.03B | $16.76B |
| Current liabilities | $1.54B | $1.45B | $1.29B | $1.26B | $2.52B |
| Long-term debt | $494.9M | $375.8M | $253.9M | $11.8M | $15.8M |
| Total liabilities | $2.15B | $2.04B | $1.97B | $1.79B | $3.21B |
| Total equity | $6.40B | $10.29B | $11.64B | $12.24B | $13.55B |
Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.
Cash flow (as reported)
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Operating cash flow | $-512.2M | $-56.9M | $138.6M | $-798.1M | $15.32B |
| Capital expenditure | $48.9M | $96.0M | $156.2M | $313.9M | $594.2M |
| Free cash flow | $-561.1M | $-152.9M | $-17.5M | $-1.11B | $14.73B |
Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.
Company facts
Selected SEC filings
Largest pharmaceutical peers
Monitor SVA
Get an alert when Sinovac Biotech files something material, see which superinvestors own it, and ask its filings a question with cited answers.
Monitor SVA freeIncludes one free filing-grounded research answer. Or check your whole portfolio, no account needed.
Data sourced from SEC EDGAR. Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only. Not investment advice.